CTRI/2024/05/066872招募中4 期
Evaluating the role of Adjuvant Capecitabine by comparing two different dose schedules with observation after standard treatment in triple negative Breast Cancer - NI
Pt B D Sharma Postgraduate Institute of Medical Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1)Patients with confirmed histopathological diagnosis of triple negative breast cancer (defined as estrogen or progesterone receptor 1+ or 2+ immunohistochemistry intensity in = 10% cells and HER2-negative by immunohistochemistry and/or in situ hybridization)
- •2)Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 2 (Annexure I) and complete hemogram, renal and liver function tests are within normal limits
- •3)Patients who are able to give consent.
- •4)Patients must have completed work up and staging followed by treatment with standard chemotherapy and surgery and /or radiation therapy.
排除标准
- •1)The presence of cancer in bilateral breasts or metastatic disease, other malignant conditions or synchronic multiple cancers.
- •2)ECOG PS 3 and above.
- •3)Patients’ refusal.
研究者
相似试验
进行中（未招募）
1 期
A Pharmacokinetic Study of Adjuvant Capecitabine in Patients who have undergone Proximal Pancreatico-Duodenectomy for Resection of Pancreatic Adenocarcinoma - Capecitabine PK Post Whipples (CAP001)For patients who have undergone proximal pancreatico-duodenectomy for resection of pancreatic adenocarcinomaEUCTR2008-008476-14-GBCambridge University Hospitals NHS Foundation Trust12
已完成
1 期
Pharmacokinetic study of adjuvant capecitabine after resection of pancreatic adenocarcinomaCancerISRCTN88098646Cambridge University Hospitals NHS Foundation Trust (UK)12
招募中
2 期
Brachytherapy with concurrent Capecitabine in advanced cervical cancerIRCT20210306050600N1Mashhad University of Medical Sciences35
进行中（未招募）
不适用
A phase II study of Capecitabine in combination with Cisplatin in advanced head and neck Cancer - NDAdvanced or metastatic head and neck cancerLevel: HLTClassification code 10024530EUCTR2006-003775-13-ITOSPEDALE ONCOLOGICO DI BARI43
进行中（未招募）
不适用
A phase II study of Capecitabine in combination with oral vinorelbine in advanced Breast Cancer - NDEUCTR2006-003752-38-ITOSPEDALE ONCOLOGICO DI BARI